BioCentury
ARTICLE | Clinical News

VTX-2337: Phase II started

July 15, 2013 7:00 AM UTC

VentiRx began the double-blind, placebo-controlled, U.S. Phase II ACTIVE8 trial to compare 3 mg/m 2 IV VTX-2337 plus standard of care (SOC: 5-FU and cetuximab plus cisplatin or carboplatin) vs. SOC alone in 175 patients with recurrent or metastatic SCCHN. Patients will receive VTX-2337 on days 8 and 15 of a 21-day cycle for 6 cycles followed by dosing on days 8 and 22 of a 28-day cycles until disease progression. ...